RZLT Rezolute, Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1509261 · Fiscal year ends 06/30
Financial factors as of 2026-09-30 (2027Q1), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY-1.0%
TTM EPS YoY20.2%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-66.9%
ROA-61.2%
ROIC (approx.)-60.4%
Asset turnover—
Leverage & solvency
Liabilities / assets10.5%
Debt / equity0.00x
Current ratio9.92x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.85x
Accruals ratio-9.4%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20262026-06-30 | FY20252025-06-30 | FY20242024-06-30 | FY20232023-06-30 | FY20222022-06-30 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | — | — | — | — | — |
| R&D expense | $53.80M | $61.53M | $55.74M | $43.81M | $32.49M |
| SG&A expense | $29.17M | $18.37M | $14.68M | $12.18M | $9.36M |
| Operating income | -$82.97M | -$79.89M | -$70.42M | -$55.99M | -$41.84M |
| Income tax | $0 | $0 | $0 | $0 | $0 |
| Net income | -$77.59M | -$74.41M | -$68.46M | -$51.79M | -$41.06M |
| EBITDA | -$82.94M | -$79.86M | -$70.39M | -$55.96M | -$41.83M |
| EPS (basic) | -0.75 | -0.98 | -1.33 | -1.01 | -2.26 |
| EPS (diluted) | -0.75 | -0.98 | -1.33 | -1.01 | -2.32 |
| Weighted avg. shares (diluted) | 103.91M | 76.00M | 51.47M | 51.19M | 19.49M |
| Balance sheet | |||||
| Cash & equivalents | $10.62M | $94.11M | $70.40M | $16.04M | $150.41M |
| Short-term investments | $97.19M | $73.75M | $56.48M | $85.86M | — |
| Current assets | $110.51M | $171.15M | $128.65M | $104.91M | $152.10M |
| PP&E, net | $41,000 | $72,000 | $103,000 | $139,000 | $16,000 |
| Total assets | $112.85M | $175.49M | $132.74M | $123.72M | $152.42M |
| Current liabilities | $11.42M | $11.91M | $9.61M | $5.20M | $2.46M |
| Total liabilities | $12.16M | $13.36M | $11.73M | $7.55M | $2.95M |
| Shareholders' equity | $100.69M | $162.13M | $121.00M | $116.17M | $149.47M |
| Shares outstanding | 96.41M | 87.00M | 53.25M | 36.83M | 33.58M |
| Cash flow statement | |||||
| Operating cash flow | -$64.64M | -$69.08M | -$57.37M | -$44.48M | -$39.62M |
| Capital expenditure | — | — | — | $153,000 | — |
| Free cash flow | — | — | — | -$44.63M | — |
| Investing cash flow | -$21.10M | -$14.54M | $48.70M | -$101.46M | — |
| Financing cash flow | $2.24M | $107.33M | $63.03M | $11.57M | $148.98M |
| Depreciation & amortization | $31,000 | $31,000 | $36,000 | $30,000 | $13,000 |
| Stock-based compensation | $14.46M | $7.12M | $7.36M | $7.27M | $3.69M |
| Share buybacks | — | — | $3,000 | — | — |
Free plan shows the latest 5 periods; Pro shows all 17 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.